Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Xeris Pharmaceuticals, Inc.
Xeris Biopharma Reports Third Quarter 2021 Financial Results and Other Highlights
November 10, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma
October 05, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 01, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 17, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma
September 14, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)
September 01, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Announces Leading Independent Proxy Advisory Firm, ISS, Recommends Xeris Stockholders Vote “FOR” the Transaction With Strongbridge Biopharma
August 30, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke® Kit for the Treatment of Severe Hypoglycemia
August 23, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Strengthens Its Patent Estate
August 19, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Achieves Unprecedented Levels of Payor Coverage for Gvoke®
August 13, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Announces FDA Acceptance of its IND Application for XeriSol™ Levothyroxine (XP-8121) for the Treatment of Hypothyroidism
August 11, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Highlights
August 05, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue
July 29, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
July 29, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Announces Executive Changes as Part of Its Strategy to Position the Company for Long-Term Commercial Success
July 28, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe
July 19, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 02, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
May 24, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma Plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
May 24, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights
May 13, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals to Webcast Upcoming Presentations
May 10, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021
May 06, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Announces Extension of the Interest-Only Period of Its Debt Facility With Oxford Finance and Silicon Valley Bank
May 06, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Receives U.K. MHRA Approval of Ogluo® (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
April 29, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Tickers
XERS
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.